ECSP045291A - Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas - Google Patents

Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas

Info

Publication number
ECSP045291A
ECSP045291A EC2004005291A ECSP045291A ECSP045291A EC SP045291 A ECSP045291 A EC SP045291A EC 2004005291 A EC2004005291 A EC 2004005291A EC SP045291 A ECSP045291 A EC SP045291A EC SP045291 A ECSP045291 A EC SP045291A
Authority
EC
Ecuador
Prior art keywords
preparation
propanodiamine
piridil
sulphamic
synthesis
Prior art date
Application number
EC2004005291A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045291A publication Critical patent/ECSP045291A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un proceso para la preparación de ácido N1-(2'-piridil)-1,2-alcanodiamino sulfámico de la fórmula (II) mediante la reacción de un compuesto de la fórmula (I) con NH2R', donde R y R', se definen en la especificación. El invento también incluye el compuesto de la fórmula (II) y los isómeros ópticos del mismo. El compuesto de la fórmula (II) es un agente intermedio útil para la preparación de derivados quirales de piperazina que son activos en el receptor de 5-HT1A.
EC2004005291A 2002-03-12 2004-09-10 Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas ECSP045291A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36345702P 2002-03-12 2002-03-12

Publications (1)

Publication Number Publication Date
ECSP045291A true ECSP045291A (es) 2004-10-26

Family

ID=28041771

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005291A ECSP045291A (es) 2002-03-12 2004-09-10 Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas

Country Status (26)

Country Link
US (1) US6784294B2 (es)
EP (2) EP1483243B1 (es)
JP (1) JP4397693B2 (es)
KR (1) KR20040091720A (es)
CN (1) CN100341854C (es)
AR (1) AR038932A1 (es)
AT (2) ATE360002T1 (es)
AU (1) AU2003220122A1 (es)
BR (1) BR0308315A (es)
CA (1) CA2477886A1 (es)
CY (1) CY1106677T1 (es)
DE (2) DE60313301T2 (es)
DK (1) DK1483243T3 (es)
EC (1) ECSP045291A (es)
ES (2) ES2334836T3 (es)
IL (1) IL163829A0 (es)
MX (1) MXPA04008731A (es)
NO (1) NO20044049L (es)
NZ (1) NZ535170A (es)
PT (1) PT1483243E (es)
RU (1) RU2314294C2 (es)
SI (1) SI1483243T1 (es)
TW (1) TWI288642B (es)
UA (1) UA80272C2 (es)
WO (1) WO2003078396A1 (es)
ZA (1) ZA200408213B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
ATE360002T1 (de) 2002-03-12 2007-05-15 Wyeth Corp Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
MXPA04008730A (es) * 2002-03-12 2004-12-06 Wyeth Corp Proceso para preparacion de piperazinas quirales 1,4-disustituidas.
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
CN101137648A (zh) * 2005-03-01 2008-03-05 惠氏公司 结晶和非晶4-氰基-n-{(2r)-2-[4-(2,3-二氢-苯并[1,4]二氧杂环己烯-5-基)-哌嗪-1-基]-丙基}-n-吡啶-2-基-苯甲酰胺盐酸盐
US8841458B2 (en) 2010-03-12 2014-09-23 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
GB201310126D0 (en) * 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586794T2 (de) 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
JPH01125357A (ja) 1987-11-06 1989-05-17 Dainippon Pharmaceut Co Ltd トリペプチドの誘導体
IL101722A (en) 1991-05-02 1996-05-14 Wyeth John & Brother Ltd Piperazine derivatives their preparation and pharmaceutical compositions containing them
WO1994024115A1 (fr) 1993-04-16 1994-10-27 Santen Pharmaceutical Co., Ltd. Nouveau derive de piperazine
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
EP0763024B1 (en) * 1994-06-03 2002-08-14 JOHN WYETH & BROTHER LIMITED Processes and intermediates for the preparation of piperazine derivatives
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
CA2251017A1 (en) 1996-04-10 1997-10-16 Mark E. Duggan .alpha.v.beta.3 antagonists
ATE360002T1 (de) 2002-03-12 2007-05-15 Wyeth Corp Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen
ATE439356T1 (de) * 2002-03-12 2009-08-15 Wyeth Corp Verfahren zur herstellung von chiralen n-aryl piperazinen

Also Published As

Publication number Publication date
RU2004130314A (ru) 2005-04-10
US6784294B2 (en) 2004-08-31
CA2477886A1 (en) 2003-09-25
ZA200408213B (en) 2007-03-28
ES2334836T3 (es) 2010-03-16
EP1483243B1 (en) 2007-04-18
DE60313301T2 (de) 2007-12-27
IL163829A0 (en) 2005-12-18
TW200303751A (en) 2003-09-16
MXPA04008731A (es) 2004-12-06
JP4397693B2 (ja) 2010-01-13
ES2283762T3 (es) 2007-11-01
NO20044049L (no) 2004-09-24
TWI288642B (en) 2007-10-21
CY1106677T1 (el) 2012-05-23
ATE360002T1 (de) 2007-05-15
DK1483243T3 (da) 2007-08-06
HK1068618A1 (en) 2005-04-29
KR20040091720A (ko) 2004-10-28
CN1642916A (zh) 2005-07-20
EP1801103A1 (en) 2007-06-27
RU2314294C2 (ru) 2008-01-10
AU2003220122A1 (en) 2003-09-29
JP2005526088A (ja) 2005-09-02
ATE449073T1 (de) 2009-12-15
BR0308315A (pt) 2004-12-28
NZ535170A (en) 2006-03-31
PT1483243E (pt) 2007-06-27
AR038932A1 (es) 2005-02-02
US20030204087A1 (en) 2003-10-30
SI1483243T1 (sl) 2007-08-31
WO2003078396A8 (en) 2004-01-29
WO2003078396A1 (en) 2003-09-25
DE60313301D1 (de) 2007-05-31
DE60330199D1 (de) 2009-12-31
CN100341854C (zh) 2007-10-10
UA80272C2 (en) 2007-09-10
EP1483243A1 (en) 2004-12-08
EP1801103B1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
CY1106677T1 (el) Παρασκευη ν1-(2’-πυριδυλ)-1, 2-προπανοδιαμινο σουλφαμικου οξεος και χρηση αυτου στη συνθεση βιολογικως δραστικων πιπεραζινων
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
AR038045A1 (es) Agentes terapeuticos
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
UY28572A1 (es) Compuestos novedosos
BR122012009534B8 (pt) 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto
UY26872A1 (es) Derivados de la 4- fenil piridina
CR8530A (es) Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
CY1107403T1 (el) Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
SE0201544D0 (sv) Novel compounds and thier use
AR010080A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
NO20054787D0 (no) Indenderivater som farmasotiske midler
PA8589801A1 (es) Aminoalcoxiindoles
BRPI0411308A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
AR034206A1 (es) Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA